Bevacizumab
CAS 216974-75-3Biologic
Overview
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to and neutralizing vascular endothelial growth factor A (VEGF-A). It is used primarily in the treatment of various cancers and certain ocular diseases.
Therapeutic areas
OncologyOphthalmology
Verified Supplier Partner
Do you supply Bevacizumab? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.